

**REMARKS**

Reconsideration and allowance are respectfully requested.

Amended claims 126, 128 and 129 overcome the objection under MPEP 608.01(n).


There is no intention to narrow the claim scope.

The application is considered in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue.

If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

By: 

Kendrew H. Colton  
Registration No. 30,368

Fitch, Even, Tabin & Flannery  
1801 K Street, N.W.  
Suite 401L  
Washington, D.C. 20006-1201  
Telephone No. (202) 419-7000  
Facsimile No. (202) 419-7007

**CLAIMS AS PRELIMINARILY AMENDED**

Please amend and/or add claims:

126. (Amended) The substance according to claim 125, comprising application of a preparation that is a modified signal substance or a modified signal substance being a zinc binding signal peptide, wherein said modified signal substance comprises interleukin 3 [as described by claim 118].

128. (Amended) The method according to claim 125 [or 126], comprising application of B-cell apoptosis inducing substances, preferably APO-1 and/or application of TGF- $\beta$  as inhibitor of B-cell antibody production.

129. (Amended) A method for stimulating stem cell-replication comprising application of a preparation that is a modified signal substance or a modified signal substance being a zinc binding signal peptide, wherein said modified signal substance comprises interleukin 3 [according to claim 118] and/or a substance obtainable according to any of the method steps according to claim 94.